65 related articles for article (PubMed ID: 38510702)
1. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
[TBL] [Abstract][Full Text] [Related]
2. Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
Gargiulo P; Basile C; Galasso G; Bellino M; D'Elia D; Patti G; Bosco M; Prinetti M; Andò G; Campanella F; Taverna G; Calabrò P; Cesaro A; Fimiani F; Catalano A; Varbella F; Corleto A; Barillà F; Muscoli S; Musumeci G; Delnevo F; Giallauria F; Napoli R; Porto I; Polimeni A; Quarta R; Maloberti A; Merlini PA; De Luca L; Casu G; Brunetti ND; Crisci M; Paloscia L; Bilato C; Indolfi C; Marzano F; Fontanarosa S; Buonocore D; Parlati ALM; Nardi E; Prastaro M; Soricelli A; Salvatore M; Paolillo S; Perrone-Filardi P;
Eur J Prev Cardiol; 2024 May; ():. PubMed ID: 38788773
[TBL] [Abstract][Full Text] [Related]
3. Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.
Zhang Z; Zhang D
Cancer Causes Control; 2024 Jun; 35(6):983-994. PubMed ID: 38430374
[TBL] [Abstract][Full Text] [Related]
4. The Causal Relationship between PCSK9 Inhibitors and Osteoporosis Based on Drug-Targeted Mendelian Combined Mediation Analysis.
Zhang N; Ji C; Liu L; Ye E; Yuan C
Calcif Tissue Int; 2024 May; ():. PubMed ID: 38789568
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy.
Krittanawong C; Khawaja M; Rosenson RS; Amos CI; Nambi V; Lavie CJ; Virani SS
Curr Probl Cardiol; 2022 Jul; 47(7):101043. PubMed ID: 34780866
[TBL] [Abstract][Full Text] [Related]
7. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
8. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
9. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
10. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study.
Xie W; Li J; Du H; Xia J
Arthritis Res Ther; 2023 Aug; 25(1):148. PubMed ID: 37580807
[TBL] [Abstract][Full Text] [Related]
11. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren's Syndrome.
Bianconi V; Cafaro G; Mannarino MR; Perricone C; Cosentini E; Bistoni O; Paltriccia R; Lombardini R; Gerli R; Pirro M; Bartoloni E
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759784
[TBL] [Abstract][Full Text] [Related]
14. IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.
Du Y; Cheng T; Liu C; Zhu T; Guo C; Li S; Rao X; Li J
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673113
[TBL] [Abstract][Full Text] [Related]
15. SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells.
D'Onofrio N; Prattichizzo F; Marfella R; Sardu C; Martino E; Scisciola L; Marfella L; Grotta R; Frigé C; Paolisso G; Ceriello A; Balestrieri ML
Theranostics; 2023; 13(2):531-542. PubMed ID: 36632236
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
